> Correction: An item in the Monday issue of FierceBiotech mistakenly states that AtheroGenics' experimental heart drug, AGI-1067, failed a primary endpoint in a trial. That trial data has not been released. The company's stock price has declined based on some investors' concerns that it may not hit its endpoint. Results are expected later this month. Report
> More bad news for Amgen, which saw its stock price dip two percent after the FDA issued a warning on Friday for Epogen and Aranesp, its two blockbuster anemia drugs. Report
> Protherics has received a $19 million milestone from AstraZeneca. Release
> Cangene has received FDA approval for a human growth hormone. Report
And Finally… If you were waiting until later to book a posh spot for the annual BIO meeting coming up in Boston this May, you might find yourself out of luck. Organizers say that more than 20,000 industry executives will turn out for the event, which is being compared to the 2004 Democratic National Convention. And the best spots are already reserved for a long lineup of events. Article